{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-005176","form_type":"8-K","ticker":"EXOZ","cik":"0002010788","company_name":"EXOZYMES INC.","filed_at":"2026-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.982329+00:00","generated_at":"2026-05-16T04:34:04.106993+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"eXoZymes reports 535g NCT pilot run at 99% conversion, 90% yield, 99.6% purity","bullets":["Achieved ~99% reaction conversion, 90% isolated yield, and 535 g of NCT at 99.6% pharma-grade purity from a 100L pilot run.","Production executed externally by Cayman Chemical, demonstrating protocol transferability and operational robustness.","High-purity NCT is now available for formulation development and partner sample requests.","Company expects 2026 focus on commercial NCT supply chain, expanded volumes, and strategic partnerships."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-005176","json":"https://secwatch.observer/filing/0001493152-26-005176.json","markdown":"https://secwatch.observer/filing/0001493152-26-005176.md","text":"https://secwatch.observer/filing/0001493152-26-005176.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2010788/000149315226005176/0001493152-26-005176-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2010788/000149315226005176/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T04:34:04.106993+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}